Phase 2 Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis
OPEN Ophthalmology | 15 Apr 2018
S Bonini, A Lambiase, P Rama, F Sinigaglia, M Allegretti, W Chao and F Mantelli
To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from impaired corneal innervation.
* Data courtesy of Altmetric.com